ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: While small-molecule tyrosine kinase inhibitors (TKIs) of BCR-Abl, such as Imatinib, have had great success in the clinic, acquired drug resistance remains a problem in treating CML effectively [29].